Tag: Bharat Biotech

The current production capacity of indigenously developed Covaxin vaccine is expected to be doubled by May-June 2021 and then increased nearly 6-7 fold by July - August 2021 under Mission COVID Suraksha......................

A lot many vaccines are expected to be granted Emergency Use Authorization in other countries for expanding the basket of vaccines for domestic use and hasten the pace and coverage of vaccination....................

Data from 25,800 participants that received the COVAXIN vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well-tolerated. It demonstrated 81% interim efficacy in preventing COVID-19 after the second dose....................

It has signed an agreement for the delivery of COVAXIN during the second and third quarter of the year 2021.....................

The representatives from the Central Asian nation of 41 million people took a tour of the world-class Bio-Safety Level 3 manufacturing facility....................

Dr Krishna M. Ella, Mrs.Suchitra Ella and Dr Balram Bhargav are being honored in BioAsia 2021...............

Recently, Bharat Biotech has applied for regulatory approval to conduct clinical trials in Bangladesh and has applied for EUA in the Philippines.....................

Ocugen to receive an initial supply of COVAXIN™ doses from Bharat Biotech upon authorization from US regulatory authorities while it ramps up manufacturing in the US. The vaccine is currently in a fully enrolled Phase 3 clinical trial involving 25,800 patients...........

Experts believe that the largest ever allocation in the history of the vaccine industry would catalyze research and development efforts in the area....................

Bharat Biotech to produce antigen for world’s first vaccine against Plasmodium falciparum malaria following technology transfer, to help ensure long-term sustainable supply. Transfer builds on GSK commitments to donate up to 10 million vaccine doses.......................